VitaSpring Biomedical Co. Ltd. (VSBC) stock
VSBCOTCServices-Commercial Physical & Biological ResearchFiscal year ends January 31
$0.03+0.00 (0.00%)
Close on Oct 19, 2026Market cap $6.58MP/E –Yield –
VitaSpring Biomedical ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
VitaSpring Biomedical's ebitda for the twelve months ending Oct 31, 2025 was -$420.48K. For fiscal 2025 it was -$669.96K.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | -$669.96K | – |
| FY2024 | Jan 31, 2024 | -$1.10M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ1 2026 | Apr 30, 2026 | -$73.36K | – |
| Q3 FY2026CQ3 2025 | Oct 31, 2025 | -$133.24K | – |
| Q2 FY2026CQ2 2025 | Jul 31, 2025 | -$96.58K | – |
| Q1 FY2026CQ1 2025 | Apr 30, 2025 | -$66.66K | – |
| Q4 FY2025CQ4 2024 | Jan 31, 2025 | -$124.01K | – |
| Q3 FY2025CQ3 2024 | Oct 31, 2024 | -$115.44K | – |
| Q2 FY2025CQ2 2024 | Jul 31, 2024 | -$216.17K | – |
| Q1 FY2025CQ1 2024 | Apr 30, 2024 | -$214.34K | – |
| Q4 FY2024CQ4 2023 | Jan 31, 2024 | -$221.63K | – |
| Q3 FY2024CQ3 2023 | Oct 31, 2023 | -$231.21K | – |
| Q2 FY2024CQ2 2023 | Jul 31, 2023 | -$349.82K | – |
| Q1 FY2024CQ1 2023 | Apr 30, 2023 | -$300.84K | – |
See a number that looks wrong?